--- title: "Cello World Limited Just Missed Earnings - But Analysts Have Updated Their Models" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/276190458.md" description: "Cello World Limited (NSE:CELLO) reported disappointing Q3 results, with revenue of ₹5.5b, 6.3% below expectations, and EPS of ₹2.88, 22% lower than forecasted. Analysts have revised their 2027 revenue forecast down to ₹25.8b (11% growth) and EPS to ₹17.33 (23% growth). The consensus price target dropped 16% to ₹587, reflecting reduced earnings outlook. Cello World's expected growth rate of 8.9% is below the industry average of 14%. Analysts express concerns over potential business headwinds and intrinsic value, despite long-term earnings estimates extending to 2028." datetime: "2026-02-18T02:11:43.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276190458.md) - [en](https://longbridge.com/en/news/276190458.md) - [zh-HK](https://longbridge.com/zh-HK/news/276190458.md) --- > 支持的语言: [English](https://longbridge.com/en/news/276190458.md) | [繁體中文](https://longbridge.com/zh-HK/news/276190458.md) # Cello World Limited Just Missed Earnings - But Analysts Have Updated Their Models It's shaping up to be a tough period for **Cello World Limited** (NSE:CELLO), which a week ago released some disappointing third-quarter results that could have a notable impact on how the market views the stock. Results showed a clear earnings miss, with ₹5.5b revenue coming in 6.3% lower than what the analystsexpected. Statutory earnings per share (EPS) of ₹2.88 missed the mark badly, arriving some 22% below what was expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. NSEI:CELLO Earnings and Revenue Growth February 18th 2026 Taking into account the latest results, the consensus forecast from Cello World's seven analysts is for revenues of ₹25.8b in 2027. This reflects a meaningful 11% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to shoot up 23% to ₹17.33. Before this earnings report, the analysts had been forecasting revenues of ₹27.9b and earnings per share (EPS) of ₹19.51 in 2027. The analysts seem less optimistic after the recent results, reducing their revenue forecasts and making a substantial drop in earnings per share numbers. See our latest analysis for Cello World The consensus price target fell 16% to ₹587, with the weaker earnings outlook clearly leading valuation estimates. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values Cello World at ₹640 per share, while the most bearish prices it at ₹515. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Cello World is an easy business to forecast or the the analysts are all using similar assumptions. One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We would highlight that Cello World's revenue growth is expected to slow, with the forecast 8.9% annualised growth rate until the end of 2027 being well below the historical 13% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 14% per year. Factoring in the forecast slowdown in growth, it seems obvious that Cello World is also expected to grow slower than other industry participants. ## The Bottom Line The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Cello World. Unfortunately, they also downgraded their revenue estimates, and our data indicates underperformance compared to the wider industry. Even so, earnings per share are more important to the intrinsic value of the business. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Cello World analysts - going out to 2028, and you can see them free on our platform here. Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here. ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ## 相关资讯与研究 - [HFCL Extends Rs 30 Crore Corporate Guarantee for Subsidiary HTL](https://longbridge.com/zh-CN/news/280883495.md) - [Rossari Subsidiary Unitop Chemicals to Sell Non-Core Mumbai Office for Rs 10 Crore](https://longbridge.com/zh-CN/news/281655433.md) - [Advantage Energy Ltd. (OTCMKTS:AAVVF) Receives Average Rating of "Moderate Buy" from Analysts](https://longbridge.com/zh-CN/news/280981094.md) - [ZyVersa Therapeutics GAAP EPS of -$4.18](https://longbridge.com/zh-CN/news/281255183.md) - [TeraGo GAAP EPS of -$0.20, revenue of $6.2M](https://longbridge.com/zh-CN/news/281028086.md)